The cannabis edibles category is about to consolidate. The November 12, 2026 federal hemp ban removes roughly $28 billion of recreational-coded hemp-derived product from the shelves of every gas station and smoke shop in the country. State-licensed dispensary edibles continue to sell. The recreational-on-recreational competition that defined the last five years is over, and the brands that survive will be the ones that picked a credible position on the medical-edibles spectrum before consolidation arrived.
The list below is not a leaderboard. It is the cohort of brands whose product fundamentals, dose precision, and condition-specific formulations point toward a future where cannabis edibles are bought the way patients buy supplements at a pharmacy, not the way college students buy gas-station gummies. Some of these names appear on our rankings. Some do not. The criteria are structural: cannabinoid ratios that map to clinical evidence, per-piece dose accuracy, condition-specific SKUs, and a customer base that includes patients alongside the wellness-curious.
What does it mean for an edibles brand to be "medical-positioned"?
Medical positioning means formulation choices that map to clinical evidence, COA-verifiable cannabinoid ratios, dose precision at a per-piece level, and condition-specific SKUs that target a real use case (sleep onset, anxiety baseline, chronic pain, nausea). It is structural, not marketing copy. Wellness branding alone does not qualify.
The distinction matters because the hemp ban is going to expose a lot of brands whose "wellness" framing was a marketing decision rather than a product decision. A pastel package with the word "calm" on it does not change the pharmacology inside. A 25mg generic gummy in pastel wrapping is the same product as the same gummy in fluorescent wrapping. Patients can tell. Patients will choose accordingly.
Real medical positioning is observable from the COA up: cannabinoid ratios chosen for a specific clinical context, per-piece variance under ten percent, condition-specific lines that survive a basic question like "what is this product for, exactly." The brands below pass that test. The brands not below do not.
Which brands are positioned for the medical-edibles transition in 2026?
Ten brands. Five built around functional or condition-targeted formulations (1906, Wana Optimals, Care By Design, Mary's Medicinals, Plus Products). Three beverage operators positioning low-dose THC as an alcohol or anxiety substitute (CANN, Brēz, Wunder). Two specialty operators with patient-leaning product lines (Papa & Barkley, Kiva Camino wellness SKUs). The hemp ban removes their loudest competitors.
1906
The canonical medical-positioned edibles brand. 1906's fast-acting tablet line splits products by intended effect (Bliss for mood, Chill for anxiety, Midnight for sleep, Genius for focus, Go for energy), with each SKU pairing a cannabinoid base with a targeted botanical (5-HTP, lavender, melatonin, caffeine, ginseng). Onset is 15 to 20 minutes via nano-emulsion. Dose precision per piece is among the best on the market, with reported variance under five percent on third-party COAs. If the medical-edibles thesis is right, 1906 is the brand best positioned to absorb the patient cohort it has been quietly building for the last eight years.
Wana Brands (Optimals)
The Optimals line from Wana Brands is the closest mass-market product to a clinical functional edible. Four condition-specific SKUs (Pain, Focus, Stay Asleep, Calm), each with cannabinoid ratios and terpene profiles tuned to the use case. The Pain SKU uses a 1:1 THC:CBD ratio with myrcene-led terpenes. Stay Asleep adds CBN. Calm uses a high-CBD ratio with linalool. The formulation logic is consistent with the published cannabinoid and terpene literature, which makes Wana the brand most likely to scale a clinically-defensible product line into a national footprint without losing the patient base.
Care By Design
The CBD-dominant brand that built its patient base in California's medical-only era and held it through the adult-use transition. Care By Design ratios run from 1:1 to 18:1 CBD:THC, which covers everything from acute-relief patients to maintenance-dose chronic pain patients who tolerate higher CBD loads. The brand has slow distribution growth outside California, Arizona, and Maryland, and the THC-led product range is thinner than competitors. Both are real limitations. The CBD-led roster is the most credible patient-program lineup outside of Mary's.
Mary's Medicinals
The longest medical-positioning track record in cannabis. Mary's pioneered the transdermal patch format in 2013, with patches delivering 10mg of THC, CBD, CBN, or a 1:1 ratio over 8 to 12 hours through controlled-release transdermal delivery. The format is the closest thing to a pharmaceutical-grade delivery mechanism in legal cannabis. Tinctures, capsules, and topical lines round out a product range built explicitly for patients on a clinical-style dosing regimen rather than for recreational consumers. Distribution is concentrated and pricing sits at the premium end. The medical credentials are the strongest on this list.
Plus Products (Sleep and Calm)
Plus Products as a whole is a benefit-segmented gummy brand, with SKUs ranging from uplift to calm to sleep. The full lineup is a mix of recreational and patient-facing positioning, but the Sleep and Calm SKUs (5mg THC plus CBN or CBD respectively) are clean medical-edibles plays. Per-piece dose precision is consistent. The 5mg dose level fits a patient using cannabinoids as a sleep aid or daytime anxiety baseline without entering recreational territory. The uplift and high-dose SKUs do not make this list; the Sleep and Calm lines do.
CANN
Defined the cannabis social tonic category and continues to lead it. The base Social Tonic line at 2mg THC plus 4mg CBD is the most-cited alcohol-alternative beverage in the market, and the Hi Boy line at 5mg is the natural step up. CANN's relevance to the medical-edibles transition runs through the wellness-anxiety overlap: patients using cannabinoids as an alcohol replacement for evening relaxation map cleanly onto the CANN dose profile. The Dusk variant (5mg THC plus 2mg CBN) is a sleep-targeted SKU that fits the patient cohort directly. National distribution is the strongest among low-dose beverage operators.
Brēz
Brēz makes the best wellness-positioned cannabis beverage on the market by product fundamentals. Against CANN's social-tonic positioning, Pabst Labs' alcohol-replica positioning, and Wunder's cannabinoid-stack experimentation, Brēz lands the cleanest medical-aesthetic. Spa-like flavor profile, clean formulation, nano-emulsion onset that matches CANN, and a brand identity that points toward the medical-edibles patient base more clearly than CANN's social-tonic framing. The product is genuinely good. The problem is pricing. At $25 to $35 for a 4-pack of 2.5mg THC beverages, Brēz delivers roughly 3x the per-milligram cost of a comparable dispensary low-dose gummy. For a wellness-affluent customer in coastal California or New York, that math works. For the medical patient cohort the brand's positioning otherwise points toward (chronic pain on a daily microdose, anxiety patient using cannabinoids as a recurring alcohol replacement, perimenopause sleep regimen), $25 a 4-pack is not sustainable as a habit. Brēz built a beautiful product for the customer who needs it least. The medical-transition thesis requires brands to find pricing that fits recurring patient consumption at the dose level a patient actually needs. The next 18 months will tell us whether Brēz can land that pricing or whether the brand stays the high-end of a category that solves cost on the lower shelves.
Wunder
Wunder pursues a multi-cannabinoid beverage strategy with THC, CBD, and CBG in each can. The low-dose precision is genuine and the lineup is one of the few that even attempts to differentiate on cannabinoid combinations rather than flavor. The brand is most interesting as a category experiment: can multi-cannabinoid beverages carve out a distinct patient cohort, or do consumers default to single-cannabinoid simplicity. Four-pack pricing is more accessible than Brēz. Distribution is still concentrated in California and select adult-use states, which limits the medical-positioning reach for patients elsewhere.
Papa & Barkley
Papa & Barkley started in topicals and moved into edibles with the same CBD-led discipline that built the topical line. The Releaf gummy range runs CBD:THC ratios from 1:1 up to 30:1, which covers the full spectrum of patient maintenance dosing. The brand emphasizes whole-plant infusion with COA transparency on every batch. The medical-positioning claim here scopes to the Releaf gummy line. Papa & Barkley's standard tinctures and capsules sit closer to the wellness-recreational center of the catalog and are not the medical-edibles play. The CBD-heavy ratios across Releaf mean less suitable for patients who need acute THC-led relief, which is a real constraint. For patients on a daily maintenance regimen for chronic pain or anxiety, Releaf is the most credible mass-market option.
Kiva Camino (Sublime and Wellness SKUs)
Camino as a whole is a recreationally-positioned premium gummy line and reads as such in the brand index. The Sublime and Wellness SKUs (Midnight Blueberry for sleep, Yuzu Lemon for daytime calm, Wild Berry for anxiety) are the parts of the lineup that survive the medical-positioning filter. Each one pairs a clear use-case framing with a dose level (5mg THC plus 2mg CBN, 1:1 ratios, etc.) that matches patient consumption patterns. The full Camino lineup is not on this list. Three of its SKUs are.
What does the hemp ban consolidation mean for the brands not on this list?
They face one of three outcomes. Pivot to compliant low-dose CBD isolate (the survival path, with thin margins). Migrate into the state-licensed channel where licenses allow it (slow, expensive, capped in most states). Or fold. The brands building medical positioning before November 12 will absorb the recreational-coded brands' customer base after.
The hemp-derived edibles cohort spent five years building a $28 billion parallel market on Farm Bill ambiguity. Section 781 closes that ambiguity with a 0.4mg-per-container total-THC cap. Most hemp brands cannot reformulate around that threshold. Cornbread Hemp, 3Chi, Delta Munchies, and the rest are either pivoting or quietly preparing to fold. For more on the channel migration map, see what the November 2026 hemp ban actually does to the edibles market.
State-licensed brands without medical positioning are at less acute risk but a longer-horizon problem. The recreational dispensary aisle in 2027 looks more competitive, not less, because the hemp consumers who migrate into dispensaries are arriving with patient-style consumption patterns: lower doses, more frequent purchase, more attention to ratios and terpenes. The recreational-coded SKUs that thrived on novelty and packaging will lose floor space to the SKUs that match those patterns.
Which of these brands should you actually try first?
Depends on your use case. For sleep onset, Plus Products Sleep or Kiva Camino Midnight. For acute anxiety, CANN Social Tonic. For chronic pain on a daily maintenance regimen, Papa & Barkley 1:18 or 1:30 ratio gummies. For occasional functional dosing across mood states, 1906 Bliss or Chill. For the strongest pharmaceutical-style delivery, Mary's Medicinals transdermal patches.
The thesis behind this list is that the next five years sort cannabis edibles into the same shape supplements found ten years ago: a few brands with real clinical credibility, a much larger number of brands that learned to imitate clinical-sounding language, and a long tail of recreational-coded SKUs that compete on flavor and packaging. The ten above sit on the credibility side. That position is the durable one. For the broader trajectory thesis, see The Cannabis Edibles Market in 2026 and Arjan Roskam on edibles replacing medicine.